Early Release – Differential Tropism of SARS-CoV and SARS-CoV-2 in Bat Cells – Volume 26, Number 12—December 2020 – Emerging Infectious Diseases journal

og eid logo 2

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Author affiliations: The University of Hong Kong, Hong Kong, China (S.K.P. Lau, A.C.P. Wong, H.K.K. Luk, K.S.M. Li, J. Fung, Z. He, F.K.K. Cheng, T.T.Y. Chan, S. Chu, K.L. Aw-Yong, P.C.Y. Woo); City University of Hong Kong, Hong Kong (T.C.K. Lau); United Christian Hospital, Kwun Tong, Hong Kong (K.S.C. Fung)

Coronavirus disease (COVID-19) is a global pandemic, affecting 213 countries with >2.7 million confirmed cases and 190,000 fatalities as of April 25, 2020 (1). Its causative agent was identified as severe acute respiratory syndrome coronavirus (SARS-CoV) 2 (SARS-CoV2), which belongs to the same coronavirus species as SARS-CoV and SARS-related CoVs (SARSr-CoVs) in horseshoe bats (genus Rhinolophus) (2,3). Given the history among some early case-patients of visiting the Huanan seafood market in Wuhan, China, and its genetic close relatedness to SARSr-CoVs in bats and pangolins (2,4), SARS-CoV-2 was suspected to have emerged from wild animals, particularly bats, similar to SARS-CoV. SARS-CoV was a recombinant virus that originated from horseshoe bats (Rhinolophus sinicus) in China before it infected palm civets and then humans (5).

Studying cellular tropism may provide clues to the host range and possible origin of zoonotic viruses. For example, SARS-CoV could replicate efficiently in kidney cells of its primary origin, R. sinicus, but not in other tested bat cells (6). To elucidate the possible origin of SARS-CoV-2, we tested susceptibilities of bat cell lines developed from different species commonly found in southern China to infection by SARS-CoV-2 in comparison with SARS-CoV. The selected bat species harbored a diverse set of coronaviruses, including SARSr-CoVs and Middle East respiratory syndrome–related coronaviruses (MERSr-CoVs), which pose potential health threats to humans (7). We also performed structural modeling of the virus/host receptor-binding interface.

SARS-CoV strain HKU-39849 was isolated in Hong Kong during the SARS epidemic as previously described (8). SARS-CoV-2 strain HK20 was isolated from a patient with COVID-19 in Hong Kong in early February 2020 (3). Thirteen primary or immortalized bat cell lines from 6 different bat species were subjected to infection with SARS-CoV and SARS-CoV-2 at multiplicity of infection of 0.1 as described previously (6,9,10), except with the addition of 2 µg/mL trypsin. The bat species included Miniopterus pusillus, Pipistrellus abramus (harboring Pipistrellus-BatCoV-HKU5), R. sinicus (harboring SARSr-BatCoVs, Rhinolophus-BatCoV-HKU2, Rhinolophus sinicus-BatCoV-HKU32), Tylonycteris pachypus (harboring Tylonycteris-BatCoV-HKU4), Rousettus leschenaultii (harboring many viruses, including Rousettus-BatCoV-HKU9 and Rousettus-BatCoV-HKU10), and Myotis ricketii (harboring Myotis-BatCoV HKU6). Vero cells from African green monkey kidney were used as positive control (Appendix). We determined viral replication efficiency by quantitative reverse transcription PCR (qRT-PCR) on cell culture supernatants (Table 1) (6). Cells were considered susceptible to viral infection if qRT-PCR on day 5 postinfection showed >1 log10 increase in viral titer with statistical significance (p<0.05 by Student t-test).

SARS-CoV but not SARS-CoV-2 can replicate efficiently in R. sinicus kidney cells; SARS-CoV showed 3.48 log10-fold increase in viral titer. In contrast, only SARS-CoV-2 can replicate in R. sinicus lung cells, but at a low viral titer (1.08 log10-fold increase). Moreover, SARS-CoV-2 can replicate more efficiently (1.46 log10-fold increase) in R. sinicus brain cells than SARS-CoV (1.09 log10-fold increase), albeit still at low viral titer (Table 2; Figure 1). Both SARS-CoV and SARS-CoV-2 can also replicate in P. abramus kidney cells with low viral titers: 1.45 log10-fold increase for SARS-CoV and 1.71 log10-fold increase for SARS-CoV-2. We observed cytopathic effects in SARS-CoV–infected R. sinicus kidney cells and SARS-CoV– or SARS-CoV-2–infected P. abramus kidney cells with rounding of cells (Appendix). We performed immunofluorescence assay on those cell lines with >1 log10-fold increase in viral load (Appendix). M. pusillus kidney cells; R. leschenaultii kidney, brain, intestine, and lung cells; T. pachypus kidney cells; and M. ricketii kidney and lung cells did not support SARS-CoV or SARS-CoV-2 infection. Furthermore, both SARS-CoV and SARS-CoV-2 replicated less efficiently in Vero cells at 33°C than at 37°C, whereas no difference in viral replication in R. sinicus kidney cells was observed between 33°C and 37°C (Appendix).

To elucidate whether the receptor-binding interface is a contributing factor for cellular tropism, we modeled the structure of the SARS-CoV-2 receptor binding domain (RBD) with that of human angiotensin-converting enzyme 2 (hACE2), R. sinicus angiotensin-converting enzyme 2 (Rs-ACE2), and P. abramus angiotensin-converting enzyme 2 (Pa-ACE2) using homology modeling by SWISS-MODEL (https://swissmodel.expasy.org) as described previously (11), based on the crystal structure of SARS-CoV-RBD/hACE2. The sequence identity between SARS-CoV RBD (template) and SARS-CoV-2-RBD (template) was >50% and the interface for all RBD/ACE2 was similar (Figure 2). We identified 11 aa differences between SARS-CoV RBD and SARS-CoV-2 RBD sequences that involved 4 of 5 critical residues for hACE2 binding in SARS-CoV RBD. Y442 was one of the 5 critical residues in SARS-CoV RBD. Because F456 is more hydrophobic than Y442 in SARS-CoV-2 RBD, it may disturb the electrostatic interaction with hACE2/Rs-ACE2. The interface for RBD/Pa-ACE 2 was similar to that of RBD/hACE2 (Figure 2), implying that Pa-ACE2 may also serve as the host receptor for SARS-CoV and SARS-CoV-2.

The ability of SARS-CoV but not SARS-CoV-2 to replicate in R. sinicus kidney cells, consistent with previous findings (12), may suggest a different evolutionary origin and path of SARS-CoV-2. SARS-CoV was most closely related to SARSr-Rs-BatCoVs from Yunnan, China, suggesting R. sinicus as its primary origin. It could also use Rs-ACE2 as receptor for cell entry (13), which may explain the efficient replication of SARS-CoV in R. sinicus kidney cells. Although SARS-CoV-2 is closely related to SARSr-CoVs in bats and pangolins, none of the existing animal viruses represents the immediate ancestor of SARS-CoV-2. SARS-CoV-2 was most closely related to SARSr-Ra-BatCoV-RaTG13 (96.1% genome identity) in Rhinolophus affinis from Pu’er, Yunnan (2), except that its RBD region was closest to pangolin-SARSr-CoV-MP789 (86.9% nucleotide identity) in smuggled pangolins from Guangdong, suggesting that SARS-CoV-2 may have evolved through recombination (3). The inability of SARS-CoV-2 to efficiently infect and replicate in R. sinicus cells may imply that R. sinicus bats were unlikely to be its proximal origin. However, bats are the primary origin of SARS-CoV, human coronavirus 229E (HCoV-229E), and probably MERS-CoV; therefore, SARS-CoV-2 most likely originated from bats. One possibility is that SARS-CoV-2 has restricted bat species tropism. Other bat species, such as R. affinis, may harbor the ancestor of SARS-CoV-2 and can be tested for cellular susceptibilities in future studies. It is also possible that SARS-CoV-2 can no longer replicate in bat cells because of substantial genetic adaptation, such as through natural evolution in an intermediate host before infecting humans.

The difference in critical residues for receptor binding between SARS-CoV and SARS-CoV-2 may have contributed to their differential infectivities in R. sinicus cells, as suggested by results from structural modeling of the receptor-binding interface. Whereas SARS RBD was most closely related to SARSr-Rs-BatCoV-WIV1 from R. sinicus, SARS-CoV-2 RBD was most closely related to the RBD region of pangolin-SARSr-CoV-MP789 from pangolins (14). Mutagenesis studies are needed to investigate whether changes of these amino acid sites may affect binding affinity to the ACE2 of different hosts and restore the infectivity of SARS-CoV-2 in R. sinicus cells.

The restricted cellular tropism of SARS-CoV and SARS-CoV-2 is different from that of MERS-CoV, which showed broad species tropism in bat cells. MERS-CoV could replicate in >5 bat cell lines (M. ricketti lung, P. abramus kidney, R. sinicus kidney and lung, and R. leschenaultii kidney cells) from 3 bat families (6). Although dromedary camels were the immediate source of MERS-CoV, bats were suggested to be the ultimate evolutionary origin (10,15). Of note, SARS-CoV, SARS-CoV-2, and MERS-CoV could all replicate in P. abramus kidneys at low titers. Structural modeling supported that P. abramus ACE2 could serve as host receptor for SARS-CoV and SARS-CoV-2. P. abramus is known to harbor Pi-BatCoV-HKU5 from the subgenus Merbecovirus (containing MERS-CoV) but not members of Sarbecovirus (containing SARS-CoV and SARS-CoV-2) (10,15). P. abramus is a potential accidental host for spillover of and source for emergence of diverse coronaviruses including SARSr-CoVs.

Dr. Lau is a professor and head of the Department of Microbiology at the University of Hong Kong. Her research focuses on microbial genomics for studying emerging infectious diseases including coronaviruses.


Suggested citation for this article: Lau SKP, Wong ACP, Luk HKH, Li KSM, Fung J, He Z, et al. Differential tropism of SARS-CoV and SARS-CoV-2 in bat cells. Emerg Infect Dis. 2020 Dec [date cited]. https://doi.org/10.3201/eid2612.202308

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *